Small molecular therapies for rheumatoid arthritis: where do we stand?
about
Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis.Probiotic bacteria: a viable adjuvant therapy for relieving symptoms of rheumatoid arthritis.The status of fostamatinib in the treatment of rheumatoid arthritis.Glorisa superba Hydroalcoholic Extract from Tubers Attenuates Experimental Arthritis by Downregulating Inflammatory Mediators, and Phosphorylation of ERK/JNK/p-38.
P2860
Small molecular therapies for rheumatoid arthritis: where do we stand?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Small molecular therapies for rheumatoid arthritis: where do we stand?
@en
Small molecular therapies for rheumatoid arthritis: where do we stand?
@nl
type
label
Small molecular therapies for rheumatoid arthritis: where do we stand?
@en
Small molecular therapies for rheumatoid arthritis: where do we stand?
@nl
prefLabel
Small molecular therapies for rheumatoid arthritis: where do we stand?
@en
Small molecular therapies for rheumatoid arthritis: where do we stand?
@nl
P2860
P1476
Small molecular therapies for rheumatoid arthritis: where do we stand?
@en
P2093
Stanley Cohen
P2860
P356
10.1517/13543784.2011.622748
P407
P577
2011-11-09T00:00:00Z